NASDAQ · SANA
Sana Biotechnology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SANA: Nov 5, 2026
Sana Biotechnology, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.15.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.18 | $-0.12 | $-0.28 | 6 |
| Dec 2026 | $-0.16 | $-0.11 | $-0.22 | 5 |
| Mar 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Jun 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest- Zacks · Jul 20, 10:49 AM EDT3 Promising Genomics Stocks to Add to Your Portfolio in 2026Genomics is reshaping healthcare, and these three stocks – MYGN, SANA and WVE – stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
- Zacks · Jul 15, 12:00 PM EDTSana (SANA) Upgraded to Buy: Here's What You Should KnowSana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Apr 17, 10:38 AM EDTWeekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections, collaborations, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Colorectal Cancer, Obesity and Fatty Liv
- RTTNews · Apr 14, 3:04 AM EDTSana Announces Strategic Collaboration With Mayo Clinic For Developing Type-1 Diabetes Therapy SC451(RTTNews) – Sana Biotechnology Inc. (SANA), a company developing engineered cell therapies, announced on Monday a strategic collaboration with Mayo Clinic for developing SC451, an investigational pancreatic islet cell therapy to treat Type-1 diabetes.
- RTTNews · Mar 20, 10:13 AM EDTWeekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal(RTTNews) – This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 D
- RTTNews · Mar 13, 10:52 AM EDTSana Biotechnology Reports Continued Positive 14-Month Results In Type 1 Diabetes Cell-Therapy Study(RTTNews) – Sana Biotechnology, Inc. (SANA) reported continued positive clinical results through 14 months from its first-in-human study evaluating islet-cell transplantation without immunosuppression, reinforcing the potential of its hypoimmune (HIP) cell-engineering platform.
- RTTNews · Mar 4, 4:25 AM ESTSana Biotech's Q4 Net Loss Expands; Plans To Submit IND For SC451 In 2026; Stock Down(RTTNews) – Sana Biotechnology, Inc. (SANA) reported fourth-quarter financial results with an expanded net loss. But on an adjusted basis, the net loss narrowed. In addition, the firm provided details on the upcoming milestones and its cash runway.
- Zacks · Feb 20, 10:48 AM ESTGenomics Stocks That Deserve a Place in Your Portfolio in 2026Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
- RTTNews · Feb 17, 9:25 AM ESTSana Biotechnology Announces Appointment Of Brian Piper As CFO(RTTNews) – Sana Biotechnology, Inc. (SANA), Tuesday announced the appointment of Brian Piper as Executive Vice President and Chief Financial Officer of the company.
- BNK Invest · Feb 4, 1:57 PM ESTCommit To Purchase Sana Biotechnology At $2.50, Earn 26% Using OptionsInvestors eyeing a purchase of Sana Biotechnology Inc (Symbol: SANA) shares, but tentative about paying the going market price of $4.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particu
- Zacks · Jan 30, 12:00 PM ESTSana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should KnowDoes Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Jan 23, 9:55 AM ESTWall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a BetThe consensus price target hints at a 74.2% upside potential for Sana (SANA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Sana Biotechnology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.